The Trading Basics
  • Politics
  • World
  • Stocks
  • Investing
  • Editor’s pick
Investing

New Harvard Study Links Lithium Deficiency to Alzheimer’s

by admin August 12, 2025
August 12, 2025

Lithium, a naturally occurring trace element in the brain, may be able to unlock a key medical mystery: why some people develop Alzheimer’s disease and others don’t, despite similar brain changes.

In a recently published study, scientists at Harvard Medical School state that lithium not only exists in the human brain at biologically meaningful levels, but also appears to protect against neurodegeneration.

Additionally, their work shows that lithium supports the function of all major brain cell types.

The decade-long study drew on mouse experiments and analyses of human brain and blood samples across the spectrum of cognitive health. The Harvard team discovered that as amyloid beta, the sticky protein associated with Alzheimer’s, begins to accumulate, it binds to lithium and depletes its availability in the brain. This drop in lithium impairs neurons, glial cells and other brain structures, accelerating memory loss and disease progression.

“The idea that lithium deficiency could be a cause of Alzheimer’s disease is new and suggests a different therapeutic approach,” said Bruce Yankner, who is the senior author of the study.

Yankner, a professor of genetics and neurology at Harvard Medical School who in the 1990s was the first to show that amyloid beta is toxic to nerve cells, said the new findings open the door to treatments that address the disease in its entirety, rather than targeting single features like amyloid plaques or tau tangles.

To explore this possibility, researchers screened for lithium compounds that could evade capture by amyloid beta.

They identified lithium orotate as the most promising candidate. In mice, the compound reversed Alzheimer’s-like brain changes, prevented cell damage and restored memory, even in animals with advanced disease.

Crucially, the effective dose was about one-thousandth of that used in psychiatric treatments, avoiding the toxicity risk that has hampered lithium’s clinical use in older patients.

“You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial,” Yankner cautioned. “But so far the results are very encouraging.”

The path to these findings began with access to an unusually rich source of brain tissue.

Working with the Rush Memory and Aging Project in Chicago, the team examined postmortem samples from thousands of donors, from cognitively healthy individuals to those with mild cognitive impairment and full-blown Alzheimer’s.

Using advanced mass spectrometry, they measured trace levels of about 30 metals. Lithium stood out as the only one whose levels dropped sharply at the earliest stages of memory loss.

The pattern matched earlier population studies linking higher environmental lithium levels, including in drinking water, to lower dementia rates. But unlike those correlations, the Harvard team directly measured brain lithium and established a normal range for healthy individuals who had never taken lithium as medication.

“Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,” Yankner said. “It’s the first time anyone’s shown that lithium exists at a natural level that’s biologically meaningful without giving it as a drug.”

To test whether this deficiency was more than an association, the researchers fed healthy mice a lithium-restricted diet, lowering brain lithium to levels seen in Alzheimer’s patients.

The animals developed brain inflammation, lost connections between neurons and showed cognitive decline; however, replenishing them with lithium orotate reversed these changes. What’s more, mice given the compound from early adulthood were protected from developing Alzheimer’s-like symptoms altogether.

The findings raise several possibilities. Measuring lithium levels in blood could become a tool for early screening, identifying people at risk before symptoms emerge. Furthermore, amyloid-evading lithium compounds could be tested as preventive or therapeutic agents, potentially altering the disease course more fundamentally than existing drugs.

For now, researchers stress that no one should self-medicate with lithium supplements.

The team emphasized that the safety and efficacy of lithium orotate in humans remain unproven, and clinical trials will be needed to determine whether the dramatic benefits seen in mice translate to people.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

0
FacebookTwitterPinterestEmail
previous post
Crypto Market Update: Bullish Targets Upsized US$4.82 Billion IPO Valuation
next post
Democratic whistleblower told FBI that Adam Schiff approved classified leaks to target Trump

You may also like

Keith Weiner: Gold, Silver in Bull Markets —...

August 13, 2025

Top 5 Small-cap Biotech Stocks of 2025

August 13, 2025

Crypto Market Update: Bullish Targets Upsized US$4.82 Billion...

August 12, 2025

Crypto Market Update: Trump Orders 401(k) Crypto Review,...

August 11, 2025

Tech 5: Tesla Pulls Plug on Dojo, Chipmakers...

August 11, 2025

OPINION — Goldenomics 102: The Shadow Price of...

August 9, 2025

Top 5 Canadian Mining Stocks This Week: Kirkland...

August 9, 2025

Significant Expansion of Douglas River Uranium Project

August 8, 2025

Helium Stocks: 5 Biggest Canadian Companies in 2025

August 8, 2025

Top 9 Global Lithium Stocks of 2025

August 7, 2025
  • S&P 500 Breaking Out Again: What This Means for Your Portfolio
  • Ashley Biden files for divorce from husband, Howard Krein, after 13 years of marriage: reports
  • More than 20 GOP attorneys general call on RFK Jr, FDA to reinstate safeguards for abortion drugs
  • Keith Weiner: Gold, Silver in Bull Markets — Here’s What’s Different This Time
  • Top 5 Small-cap Biotech Stocks of 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    • Privacy Policy
    • Terms & Conditions

    Disclaimer: thetradingbasics.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thetradingbasics.com | All Rights Reserved

    The Trading Basics
    • Politics
    • World
    • Stocks
    • Investing
    • Editor’s pick